Drugs / RQ-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06063330 | Sep 2023 → Jan 2024 | COVID-19 | Red Queen Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RQ-01 | “Drug product RQ-001 is the fully assembled device consisting of the vial containing RQ-01 and the actuator.” NCT06063330 ↗ |
| Route | Intranasal | “Subjects will be exposed to RQ-01 after nasal administration with the Aptar Bidose nasal spray device (BDSI V3).” NCT06063330 ↗ |